Kyle Bass targets Alpex speckled tablet patent

Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board (PTAB) review the validity of a patent owned by Alpex Pharma.

Bass is named alongside Erich Spangenberg as requesting that an inter partes review (IPR) trial should be instituted against Alpex’s patent called “ orally disintegrating tablets with speckled appearance”.

Bass, whose Coalition for Affordable Drugs organisation has previously filed a number of IPR petitions, is named in a personal capacity on the petition. The coalition is not named.

The disputed patent is US number 8,440,170 and is due to expire in 2029.

The petition was filed on November 24.

Bass has argued that the patent is obvious and that an IPR should be instituted because there is “a reasonable likelihood of prevailing” at trial.